Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This trial will assess the efficacy of CRx-401 in lowering FPG levels in patients taking
metformin to treat their diabetes. In addition, this initial trial will evaluate insulin
resistance (HOMA-IR index), HgbA1c levels, glycated protein, LDL, HDL, triglycerides, and
total cholesterol, as well as the safety of CRx-401.